# CDI-988 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/cdi-988

> CDI-988, sponsored by Cocrystal Pharma, Inc. (COCP): 6 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: half-year only, month only, quarter only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | CDI-988 |
| Codes | CDI-988 |
| Sponsor | Cocrystal Pharma, Inc. (COCP) https://sec-api.dev/companies/cocp/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | fast track |

## Timeline

### late 2024: topline data readout

- Status: scheduled. Date confidence: half. Stage: 1.
- First seen 2024-11-13, last confirmed 2024-11-13.
- Press release filed with the SEC (EX-99) (accession 0001493152-24-045083): ""The multiple-ascending dose portion in our Phase 1 pan-norovirus/pan-coronavirus study with oral protease inhibitor CDI-988 is underway and we are on track to report topline results in late 2024 or early 2025," he added." https://www.sec.gov/Archives/edgar/data/1412486/000149315224045083/ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001493152-24-045083): "○ We expect to report topline results from the CDI-988 Phase 1 study in late 2024 or early" https://www.sec.gov/Archives/edgar/data/1412486/000149315224045083/ex99-1.htm

### Sep 2024: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2024-11-13, last confirmed 2026-08-13.
- SEC Form 10-Q (accession 0001493152-26-037573): "September 2024 we initiated dosing of the first subjects in the multiple-ascending dose (MAD) portion of the Phase 1 study with CDI-988." https://www.sec.gov/Archives/edgar/data/1412486/000149315226037573/form10-q.htm
- SEC Form 10-Q (accession 0001493152-26-023377): "September 2024 we initiated dosing of the first subjects in the multiple-ascending dose (MAD) portion of the Phase 1 study with CDI-988." https://www.sec.gov/Archives/edgar/data/1412486/000149315226023377/form10-q.htm
- SEC Form 10-K (accession 0001493152-26-013838): "September 2024 we initiated dosing of the first subjects in the multiple-ascending dose (MAD) portion of the Phase 1 study with CDI-988." https://www.sec.gov/Archives/edgar/data/1412486/000149315226013838/form10-k.htm
- SEC Form 10-Q (accession 0001493152-25-022581): "September 2024, we initiated dosing of the first subjects in the multiple-ascending dose (MAD) portion of the Phase 1 study with CDI-988." https://www.sec.gov/Archives/edgar/data/1412486/000149315225022581/form10-q.htm
- SEC registration statement (S-1) (accession 0001493152-25-014266): "September 2024 we initiated dosing of the first subjects in the multiple-ascending dose (MAD) portion of the Phase 1 study with CDI-988." https://www.sec.gov/Archives/edgar/data/1412486/000149315225014266/forms-1.htm
- SEC prospectus (424B) (accession 0001493152-25-013400): "September 2024 we initiated dosing of the first subjects in the multiple-ascending dose (MAD) portion of the Phase 1 study with CDI-988." https://www.sec.gov/Archives/edgar/data/1412486/000149315225013400/form424b5.htm
- SEC Form 10-Q (accession 0001641172-25-023728): "September 2024, we initiated dosing of the first subjects in the multiple-ascending dose (MAD) portion of the Phase 1 study with CDI-988." https://www.sec.gov/Archives/edgar/data/1412486/000164117225023728/form10-q.htm
- SEC Form 10-Q (accession 0001641172-25-010539): "In September 2024 we initiated dosing of the first subjects in the multiple-ascending dose (MAD) portion of the Phase 1 study with CDI-988." https://www.sec.gov/Archives/edgar/data/1412486/000164117225010539/form10-q.htm
- SEC Form 10-Q (accession 0001493152-24-044978): "September 2024 we initiated dosing of the first subjects in the multiple-ascending dose (MAD) portion of the Phase 1 study with CDI-988." https://www.sec.gov/Archives/edgar/data/1412486/000149315224044978/form10-q.htm

### Q2 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 1.
- First seen 2025-03-31, last confirmed 2025-05-15.
- Press release filed with the SEC (EX-99) (accession 0001641172-25-010537): "o We expect to report topline oral CDI-988 Phase 1 results from the high-dose healthy subject cohort in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1412486/000164117225010537/ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001641172-25-001494): "○ We expect to report topline results from the high-dose healthy volunteer cohort with CDI-988 in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1412486/000164117225001494/ex99-1.htm
- SEC Form 10-K (accession 0001641172-25-001496): "The topline data of the MAD cohorts, including based on an additional cohort with a higher dose of 1200 mg and a shorter treatment duration of five consecutive days, is expected to be released in the first half of 2025." https://www.sec.gov/Archives/edgar/data/1412486/000164117225001496/form10-k.htm

### Q1 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 1.
- First seen 2025-01-08, last confirmed 2025-11-14.
- Press release filed with the SEC (EX-99) (accession 0001493152-25-022603): "Expects to initiate CDI-988 Phase 1b norovirus challenge study in Q1 2026" https://www.sec.gov/Archives/edgar/data/1412486/000149315225022603/ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001493152-25-022603): "This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our plans for the future development of preclinical and clinical product candidates including the potential of our norovirus product candidates, our plans to initiate a human Phase 1b challenge study for our norovirus product candidate CDI-988 in early 2026, and our plans with regard to continued development of CC-42344, the potential characteristics and benefits of and market for our product candidates, and potential future capital we may receive from warrant exercises for cash." https://www.sec.gov/Archives/edgar/data/1412486/000149315225022603/ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001493152-25-001314): ""We expect to begin enrollment in the Phase 1 study higher-dose cohort in the current quarter and to initiate a human challenge study in norovirus-infected subjects later in 2025."" https://www.sec.gov/Archives/edgar/data/1412486/000149315225001314/ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001641172-25-027247): "This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential efficacy of CDI-988 as a potential antiviral for the prevention and treatment of norovirus infection, and the Company's plan to initiate a Phase 1b study in 2025." https://www.sec.gov/Archives/edgar/data/1412486/000164117225027247/ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001641172-25-023727): "◌ We plan to initiate a human challenge Phase 1b study in the U.S. in 2025 to evaluate CDI-988 as a norovirus prophylaxis and treatment." https://www.sec.gov/Archives/edgar/data/1412486/000164117225023727/ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001641172-25-022153): "This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential efficacy of CDI-988 as a potential breakthrough for norovirus prophylaxis and treatment, and the potential characteristics of and market for such product candidate and the Company's plan to initiate a Phase 1b study in 2025." https://www.sec.gov/Archives/edgar/data/1412486/000164117225022153/ex99-1.htm

### March 9, 2026: trial start

- Status: completed. Date confidence: exact. Stage: 1.
- First seen 2026-03-09, last confirmed 2026-03-09.
- Press release filed with the SEC (EX-99) (accession 0001493152-26-009309): "announces the first subjects have been dosed in a Phase 1b norovirus challenge study (NCT07198139) to evaluate CDI-988 as both a preventive and treatment for norovirus infections." https://www.sec.gov/Archives/edgar/data/1412486/000149315226009309/ex99-1.htm

### Q4 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 1.
- First seen 2026-08-03, last confirmed 2026-08-03.
- Press release filed with the SEC (EX-99) (accession 0001493152-26-035743): ""We expect to report topline data from our Phase 1b norovirus trial by the end of the fourth quarter of 2026, and we're grateful for OPKO's continued conviction in the value of our lead asset, CDI-988, and our broader antiviral pipeline spanning influenza, coronaviruses and hepatitis C."" https://www.sec.gov/Archives/edgar/data/1412486/000149315226035743/ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001493152-26-035743): "The Company's lead program, CDI-988, is currently in a Phase 1b clinical trial for norovirus, with topline data expected in late 2026." https://www.sec.gov/Archives/edgar/data/1412486/000149315226035743/ex99-1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/cdi-988.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CDI-988 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/cdi-988

```bibtex
@misc{secapidev_pdufa_cdi_988_20261116,
  title        = {CDI-988 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/cdi-988}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_cdi_988_20261116","title":"CDI-988 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/cdi-988","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
